Key result
Third-generation everolimus-eluting stents linked to ~12% greater strut coverage versus second-generation stents in autopsies.
Why the study?
Pathological changes after third-generation drug-eluting stent implantation remain unclear.
Does third-generation everolimus-eluting stent improve arterial healing and neointimal coverage compared to second-generation everolimus-eluting stent in human autopsy cases and an atherosclerotic porcine model?
Observational (n=13)
Yes
Does third-generation everolimus-eluting stent improve arterial healing and neointimal coverage compared to second-generation everolimus-eluting stent in human autopsy cases and an atherosclerotic porcine model?
Third-generation biodegradable-polymer everolimus-eluting stents demonstrate more rapid arterial healing with better strut coverage and less fibrin deposition compared to second-generation durable-polymer stents.
Autopsy data should not change stent selection; leaves open whether better coverage improves clinical outcomes.
Pathological changes after third-generation drug-eluting stent implantation remain unclear. We compared the tissue responses of coronary arteries after the implantation of third-generation abluminal biodegradable-polymer everolimus-eluting stent (3rd EES) and second-generation durable-polymer EES (2nd EES) using autopsy specimens and an atherosclerotic porcine model. We compared the histology of stented coronary arteries obtained by autopsy performed 1-10 months after 3rd EES (n (number of cases) = 4, stent-implanted period of 3-7 months) and 2nd EES (n (number of cases) = 9, stent-implanted period of 1-10 months) implantations. The ratio of covered stent struts was higher with 3rd EESs than with 2nd EESs (3rd; 0.824 ± 0.032 vs. 2nd; 0.736 ± 0.022, p = 0.035). Low-density lipoprotein receptor knockout minipigs were stented with 3rd or 2nd EES in the coronary arteries and the stented regions were investigated. The fibrin deposition around the 2nd EES was more prominent. Additionally, higher density of smooth muscle cells was confirmed after the 3rd EES implantation. Pathological examination after the 3rd EES demonstrated a combination of less fibrin deposition and more rapid acquisition of well-developed neointima as compared to the 2nd EES at autopsy and the atherosclerotic porcine model.
No takes yet. Share an insight, caveat, or question.
Migita et al. (2021) conducted an observational in Coronary artery disease (post-stent implantation) (n=13). Third-generation abluminal biodegradable-polymer everolimus-eluting stent (3rd EES) vs. Second-generation durable-polymer everolimus-eluting stent (2nd EES) was evaluated on Ratio of covered stent struts (p=0.035). Third-generation everolimus-eluting stents demonstrated a significantly higher ratio of covered stent struts compared to second-generation stents (0.824 vs 0.736) in human autopsy cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: